Drug intelligence / Profile preview

Innerim

Development stage: Preclinical
Lead developer: AB-BIOTICS
Modality: Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Innerim is a probiotic formula developed by AB-BIOTICS (a Kaneka Group company) specifically designed for the "healthy ageing" market. It is formulated to address health challenges associated with aging, including immunosenescence (the age-related decline of the immune system), nutritional deficiencies, and chronic constipation. The product functions by modulating the gut microbiota to restore microbial balance, which in turn supports systemic immune surveillance and improves gastrointestinal motility. Innerim is typically categorized as a nutraceutical or dietary supplement rather than a prescription pharmaceutical drug.

Brand names: Innerim
Other names: Innerim®

Beyond the preview

Go deeper on Innerim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innerim.

Explore the full profile